Overexpression of the Ras-signaling pathway in KRAS-mutant CRC disrupts the downstream signal transduction of anti-EGFR therapy that renders KRAS-mutant CRC resistant to cetuximab [29]. Here, EGFR is linked to colorectal carcinoma.